Publication | Open Access
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*
35
Citations
15
References
2021
Year
Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival.
| Year | Citations | |
|---|---|---|
Page 1
Page 1